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ABSTRACT
INTRODUCTION: Progressive systemic sclerosis (PSS) is a connective tissue disorder with unknown eti-
ology, characterized by increased collagen deposition leading to fibrosis, skin thickening and other patho-
logical changes in organs. Females constitute at least two-thirds of all the cases. The disease commonly oc-
curs in women aged 30-40 years. Other features of the disease include Raynaud’s phenomenon, telangiecta-
sia, calcinosis, myositis, arthritis, tenosynovitis, renal failure, esophageal dysmotility, pulmonary fibrosis, 
and heart failure.
MATERIALS AND METHODS: A 71-year-old female was hospitalized with ischemic and cyanotic fin-
gertips in the Department of Rheumatology, St. Marina University Hospital, Varna, Bulgaria. She com-
plained of pain in both hip joints when walking, erythema in the region of the distal phalanges of the hands 
and feet with individual ulcerations on the fingertips. Raynaud’s phenomenon was positive. Other comor-
bidities that were included in her medical records were type two diabetes, hypertension, and past histo-
ry of endometrial cancer. The physical exam revealed sclerodactyly, cutaneous sclerosis of hands and feet, 
and microstomia. Laboratory tests revealed high levels of very low-density lipoprotein (4.9) and high level 
of blood sugar (7.2). Immunology revealed high levels of antinuclear antibodies (+++), anti-centromere pro-
tein B (++), anti-Sjögren’s syndrome-A (Ro52) (+++). 
RESULTS: The following medications were administered: methylprednisolone 40 mg intravenous, raniti-
dine 150 mg 2х1 per os, pulse therapy with cyclophosphamide amp 1000 mg in 500 mL saline, then followed 
by another bank of 500 mL saline, metoclopramide 10 mg - 1 ampoule intravenously, and heparin 2x500E 
intravenous.
CONCLUSION: The occurrence of the disease in such an advanced age is unlikely, while the risk of diabe-
tes and neoplasia increases exponentially with the age.  The uniqueness of the case herein lies with its late 
presentation, which could easily be misinterpreted as a complication of her concomitant diseases.  
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INTRODUCTION 
Systemic sclerosis (SSc) is a chronic system-
ic autoimmune disease characterized by microangi-
opathy, increased deposition of extracellular matrix 
with progressive fibrosis, both in the skin and in vis-
ceral organs that can involve the lungs, heart, kid-
neys, and the gastrointestinal tract (1).
Many factors, including environmental ones, 
can lead to immunologic system disturbances and 
vascular changes. Endothelial alterations may lead to 
a cascade of stimulatory changes that involve many 
cells, including fibroblasts, T-lymphocytes, macro-
phages, and mast cells. In turn, the activated cells se-
crete a variety of substances, including cytokines and 
their soluble receptors and enzymes and their inhib-
itors. These substances lead to changes in the extra-
cellular matrix compounds, including fibronectin; 
proteoglycans; and collagen types I, III, V, and VII. 
Increased collagen production or disturbances in 
its degradation can cause excessive collagen deposi-
tion in tissues. The tissue lesions in various stages of 
scleroderma are charcterized by early microvascular 
damage, mononuclear cell infiltrates, and slowly de-
veloping fibrosis. In later stages of scleroderma, the 
main findings are very densely packed collagen in 
the dermis, loss of cells, and atrophy. Although skin 
fibrosis is the distinguishing hallmark, the patholog-
ical changes in the lungs, gastrointestinal tract, kid-
neys, and heart determine the clinical outcome. In 
general, the extent of skin involvement and its rate 
of progression reflect the severity of visceral organ 
complications (2,3). 
A striking feature of systemic sclerosis is its pa-
tient-to-patient variability, and heterogeneity has 
been observed in clinical manifestations, autoan-
tibody profiles, the rate of disease progression, re-
sponse to treatment and survival. Based on the ex-
tent of their skin involvement, patients are grouped 
into limited cutaneous systemic sclerosis (lcSSc) and 
diffuse cutaneous systemic sclerosis (dcSSc) sub-
sets. In lcSSc, skin fibrosis is restricted to the fingers 
(sclerodactyly), distal extremities and face, whereas 
in dcSSc, the trunk and proximal extremities are also 
affected. In patients with lcSSc, Raynaud’s phenom-
enon typically precedes skin involvement and other 
disease manifestations by months to years, whereas 
patients with dcSSc have rapid disease progression 
with extensive skin changes and early development 
of visceral organ complications (2). 
Autoantibodies are particularly helpful in sys-
temic sclerosis for both diagnosis and classification. 
lcSSc is more commonly associated with centromere-
specific antibodies, whereas dcSSc is more often as-
sociated with topoisomerase I- or RNA polymerase 
III-specific antibodies. However, not all patients with 
systemic sclerosis fall clearly into one of these two 
disease subsets, and some can change their subset as-
signment over time (2).
CASE PRESENTATION
A 71-year-old female was hospitalized with 
ischemic and cyanotic fingertips in the Depart-
ment of Rheumatology, St. Marina University Hospi-
tal, Varna, Bulgaria. She complained of pain in both 
hip joints when walking. Erythema was observed in 
the region of the distal phalanges of the hands and 
feet with individual ulcerations on the fingertips and 
Raynaud’s phenomenon was positive. Other comor-
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bidities, which were included in her medical records, 
were type two diabetes, hypertension and past histo-
ry of endometrial cancer. The vital signs were blood 
pressure of 130/80 mmHg, and pulse of 75 bpm. On 
physical examination the skin was pale pink, indu-
rated and upon testing, its tightness taking hold of a 
plica was hindered in the area of the hands, feet, and 
face. The visible mucosa was without deviations. The 
fingers were pale with low local temperature with 
multiple ulcerations and indurations. Laboratory test 
results: Hb: 103 g/L, leukocytes: 4.22 10^9/L, plate-
let count: 181 10^9/L. urea: 5.5 mmol/L; creatinine: 
63 mcmol/L; random plasma glucose: 7.1 mmol/L, 
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quantitative: 0.47 mg/L; antinuclear antibodies 
(ANA) (+++), anti-centromere protein B (antiCEMP-
B) (++), anti-Sjögren’s syndrome-A (Ro52) (anti-SS-
A) (+++). Abdominal ultrasound revealed a persist-
ing oval paraaortic lesion on the left with an approx-
imate size of 38/42mm and a cortical cyst in the left 
kidney with an  approximate size of 37/22mm. 
RESULTS
The following medications were administered 
intravenously: methylprednisolone 40 mg, ranitidine 
150 mg 2х1 per os, pulse therapy with cyclophos-
phamide amp 1000 mg in 500 mL saline, then fol-
lowed by another bank of 500 mL saline, metoclo-
pramide 10 mg - 1 ampoule intravenously,  and hep-
arin 2x500E.
DISCUSSION
Scleroderma is an autoimmune disorder in-
volving multiple systems, thus making the course of 
this disease unpredictable. Though the exact nature 
of the disease is not known, high prevalence of cir-
culating autoantibodies in serological investigations 
points toward an autoimmune mechanism (4).
In this case, a 71-year-old female patient was 
with main complaints of pain in both hip joints when 
walking, erythema in the region of the distal phalan-
ges of the hands and feet with individual ulcerations 
on the fingertips. On physical examination, sclero-
sis lesions, sclerodactyly on fingers and toes, telan-
giectasia in the region of the hands and feet were 
reported.
Laboratory test results: CRP quantitative: 0.47 
mg/L, antinuclear antibodies (ANA) (+++), anti-cen-
tromere protein B (antiCEMP-B) (++), anti-Sjögren’s 
syndrome-A (Ro52) (anti-SS-A) (+++) with the con-
clusion: scleroderma. 
In 2013, a revised classification criteria — the 
American College of Rheumatology (ACR)–Euro-
pean League Against Rheumatism (EULAR) crite-
ria — were proposed to address some of the difficul-
ties in the classification and diagnosis of scleroder-
ma (Table 1). In this case, the patient had skin thick-
ening of the fingers of both hands extending proxi-
mally to the metacarpophalangeal joints, sclerodac-
tyly of the fingers, individual fingertip lesions with 
pitting scars, telangiectasia, Raynaud’s phenomenon, 
SSc-related autoantibodies, and the score was 24. The 
patient was then diagnosed with scleroderma.  
CONCLUSION
The management for systemic scleroderma con-
sists of 1) counseling and psychological support; 2) 
management of the skin and joints; 3) management 
of Raynaud’s phenomenon; 4) drug therapy; 5) im-
munotherapy; and 6) management of complications.
  Counselling and psychological support are-
needed to alleviate the burden of the disease and 
in increasing the quality of life for the patient. 
  Methylprednisolone 40 mg i.v. is administers as 
an anti-inflammatory agent.
  Ranitidine 150mg 2х1 p.o. is administered as an 
antiulcerative agent.
  Cyclophosphamide amp 1000 mg pulse therapy 
is used as an immunosuppressant.
  Metoclopramide 10 mg - 1 ampoule i.v.  is used 
as an antiemetic.
  Heparin 2x500E i.v. is administered as an 
anticoagulant.
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